President Donald J. Trump is determined to make the American pharmaceutical and biotechnology industries great again — both as a matter of national security and to unleash unprecedented prosperity for American workers.Gilead Sciences became the latest industry leader to announce a massive new investment in its U.S. operations with an $11 billion boost to its planned U.S.-based spending.The company joins a host of others in expanding their domestic footprint to align with President Trump’s vision:New Jersey-based Johnson & Johnson announced a $55 billion investment in manufacturing, research and development, and technology.Roche, a Swiss drug and diagnostics company, announced a $50...